Illumina/Agilent deal raises genome sequencing ante

Agilent and Illumina recently announced a comarketing agreement aimed to help the two technology leaders further penetrate the $3 billion genomics space. According to the companies, Agilent's SureSelect Target Enrichment System will allow researchers to home in on small variations in large gene sequ...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Oxford Nanopore prepares for a $3 billion IPO

News Commentary | April 01, 2021

Oxford Nanopore's nanopore technology has come into the limelight since the COVID‑19 outbreak. Since then, it has supported scientists in over 85 countries in tracking the emergence of new mutant variants. This field validation and its ability to overcome various technical hurdles sets the stage for... To read more, click here.

Scientists develop a method to detect COVID-19 and its variants simultaneously

News Commentary | May 31, 2021

There are various methods to screen individuals for COVID‑19 today. However, these tests only tell you if you're "positive" or "negative" for COVID‑19. They do not give you details about which variants you may have if you test positive. That requires a further sequencing step to confirm, which may ... Not part of subscription

Human Genomics

Technology | August 25, 2021

The sequencing, analysis, and interpretation of the human genome, which leads to therapeutic, diagnostic, and wellness applications. Not part of subscription